Clinical Trial Update: Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial to evaluate a vaccine therapy with or without sargramostim in patients with high-risk or metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Vaccine therapy
• sargramostim (sargramostim)

Snippet

Sponsor: Herbert Irving Comprehensive Cancer Center | Conditions: Melanoma (Skin) | Phase 1 | Status: UNKNOWN